Vamorolone FDA approval (Catalyst Pharmaceuticals – NASDAQ:CPRX)

FDA just approved Vamorolone in the treatment of Duchenne Muscular Distrophy in the US.
https://www.globenewswire.com/news-release/2023/10/26/2767947/0/en/Catalyst-Pharmaceuticals-Reports-FDA-Approval-of-AGAMREE-vamorolone-for-Duchenne-Muscular-Dystrophy-Granted-to-Santhera-Pharmaceuticals.html

Catalyst Pharmaceuticals had acquired the rights to Vamorolone in late June from Santhera Pharmaceuticals Holding AG (a swiss company).
The latter will focus on the European market.

Vamorolone is an alternative to cortisone in the treatment of DMD (it has the same effects but way less side effects).

My thesis is that Vamorolone will slowly replace Cortisone in every aspect.